When is a heart transplant considered in amyloidosis, and who qualifies? In this session, we break down how doctors evaluate candidacy, how disease type (ATTR vs AL) and timing impact outcomes, and what life looks like after transplant. We’ll cover risks, recovery, and how transplant fits with modern therapies so you can make informed decisions with your care team.

Dr. Hasan Siddiqi is an advanced heart failure cardiologist who is the director of the cardiac amyloidosis program and assistant professor of medicine at Vanderbilt Univ Medical Center in Nashville, TN. He is board certified in internal medicine, cardiology, heart failure, cardiac transplantation and echocardiography. Dr. Siddiqi is involved in multiple studies and trials in the treatment of cardiac amyloidosis patients, as well as being developing a novel research program for cardiac amyloidosis at Vanderbilt University. In addition to cardiac amyloidosis, Dr. Siddiqi also manages patients with heart failure, ventricular assist devices and heart transplantation in his clinic, in the ICU and inpatient units. Dr. Siddiqi graduated from Harvard College with a degree in neurobiology, then went to the Univ of Michigan for medical school and his masters in clinical research, followed by residency at the University of Pennsylvania. He then pursued cardiology, heart failure and transplantation fellowships at Brigham and Women's Hospital/Harvard Medical School, following which he was appointed assistant professor of medicine at Vanderbilt Univ. He lives with his wife and two young children in Nashville, TN.

This talk explores how disruption can open the door to deeper awareness. Participants learn to tune into inner guidance, body signals, and life’s patterns, shifting from “why me” to “what is this teaching me.” With intention and practice, challenges become meaningful, strengthening connection to something larger and sustaining.

Meredith Caplan works with individuals and groups to promote inner awareness in alignment with our innate knowing and capacity for thriving.

Meredith has a B.A. from Yale University and a J.D. from Boston University School of Law. She worked as: a human rights lawyer; a women’s rights advocate; an adjunct professor; and the Director of Strategic Initiatives at the Spirituality Mind Body Institute, Teachers College, Columbia University. 

Wondering if your ATTR-CM treatment is truly working? Learn how to track meaningful signs of progress, what tests and symptoms matter most, and how to partner with your care team. Walk away with practical tools to assess your response and make confident, informed decisions about your care.

Rebecca R. Hung, M.D., Ph.D., is an assistant professor of clinical medicine in the Division of Cardiovascular Medicine at Vanderbilt University Medical Center.

What is transthyretin (TTR) and why does it matter so much in amyloidosis? This session breaks down the role of TTR in the body, how it becomes unstable, and what leads to amyloid buildup. 

Sarah Paciulli is a certified family nurse practitioner who founded VCU Health’s cardiology navigator program and leads transitional care for heart failure and myocardial infarction patients. She specializes in cardiac amyloidosis, contributes to clinical research and state advisory efforts, and has received multiple awards for clinical excellence.